This week, four pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This week, NuPathe Inc. (PATH) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

This week, Watson Pharmaceuticals (WPI) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

RedHill Biopharma Ltd. Sponsored ADR (RDHL) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of RDHL stock.

Bristol-Myers Squibb Company (BMY) shows solid improvement this week. The company’s rating rises from a C to a B. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.